AI Article Synopsis

  • - The study aimed to compare the effectiveness and safety of two treatments for cutaneous leishmaniasis: intramuscular meglumine antimoniate and oral miltefosine.
  • - Conducted from January to December 2021 on 66 male patients aged 18-60, results showed a higher treatment success rate for meglumine antimoniate, but it also had more side effects leading to patient withdrawals.
  • - The conclusion indicated that while meglumine antimoniate was more effective, its associated side effects raise concerns about its overall safety compared to miltefosine.

Article Abstract

Objective: To compare the efficacy and safety of meglumine antimoniate and miltefosine in the treatment of cutaneous leishmaniasis in Pakistan.

Study Design: Randomised-controlled trial. Place and Duration of the Study: Department of Dermatology, Combined Military Hospital, Lahore and Peshawar, from January to December 2021.

Methodology: Smear positive and/or skin biopsy-confirmed cases of cutaneous leishmaniasis in adult males aged between 18-60 years were enrolled after receiving informed consent. Patients were randomly divided into Group A and Group B by lottery method. Group A received intramuscular meglumine antimoniate 15-20mg/kg/day, and Group B received oral miltefosine 50 mg thrice a day for a duration of 28 days. Data were analysed by SPSS 22. Effectiveness and safety of therapeutic agents were calculated by Independent t-test and p-value of 0.05 or less was taken as significant.

Results: Sixty-six patients, 33 in each group, participated in the study. Total number of cutaneous leishmaniasis lesions were 77 in Group A and 76 in Group B. The duration of lesions was 3.5 months in Group A and 3.2 months in Group B. Treatment response, in terms of complete or near complete resolution of lesions, was significantly higher in Group A as compared to Group B (p = 0.011). Both therapeutic agents had considerable side-effects with more patients withdrawn from Group A as compared to Group B (p = 0.010).

Conclusion: Intra-muscular meglumine antimoniate was more effective in comparison to oral miltefosine in the treatment of cutaneous leishmaniasis. However, efficacy of meglumine antimoniate is mired by its side-effect profile.

Key Words: Cutaneous leishmaniasis, Meglumine antimoniate, Miltefosine, Efficacy, Side-effects, Adverse effects, Safety, Treatment, Old world cutaneous leishmaniasis.

Download full-text PDF

Source
http://dx.doi.org/10.29271/jcpsp.2023.12.1367DOI Listing

Publication Analysis

Top Keywords

cutaneous leishmaniasis
28
meglumine antimoniate
24
group
13
antimoniate miltefosine
12
treatment cutaneous
12
miltefosine treatment
8
group group
8
group received
8
oral miltefosine
8
therapeutic agents
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!